Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616946 | 0.73 | L3MBTL1 (0.42) | MAPTUSP2ALDH1A1MAPK1TSHR | |
| SCHEMBL597029 | 0.67 | NAMPT (0.46) | MAPTTSHRSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL597171 | 0.67 | NAMPT (0.46) | MAPTTSHRSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL597028 | 0.67 | NAMPT (0.46) | MAPTTSHRSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL10326190 | 0.65 | DPP4 (0.51) | DPP4USP2ALDH1A1MAPK1TSHR | |
| SCHEMBL8545758 | 0.65 | HPGD (0.41) | DPP4ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL28098919 | 0.65 | MAPK1 (0.34) | MAPK1KMT2A | |
| Ammonia Solution, Strong SCHEMBL26111130 | 0.64 | DPP4 (0.50) | DPP4USP2ALDH1A1MAPK1TSHR | |
| Hydrochloric Acid SCHEMBL15264500 | 0.64 | DPP4 (0.50) | DPP4USP2ALDH1A1MAPK1TSHR | |
| SCHEMBL3633044 | 0.64 | MAPT (0.39) | MAPTALDH1A1TSHRSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | DPP4 532/4885MAPT 4494/4885USP2 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.